NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
Clinical Trials
50 trialsNCT00993044 2023-10-06
VIT-B
Children's Hospital Los Angeles
Phase 1 Completed
NCT02588105 2022-09-19
AToM
AstraZeneca
Phase 1 Completed
NCT02250157 2022-02-22
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Athenex, Inc.
Phase 1 Completed
NCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT02392793 2021-02-09
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02157792 2020-04-01
M6620 First in Human Study
EMD Serono
Phase 1 Completed
NCT00002902 2019-03-13
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01634555 2019-02-26
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Phase 2 Completed
NCT00215501 2018-11-02
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01009073 2017-11-20
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie
Phase 1 Completed
NCT01593228 2017-09-19
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Sanofi
Phase 3 Completed
NCT00186979 2017-04-26
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00731276 2017-03-31
Irinotecan in Treating Asian Patients With Solid Tumors
National Cancer Centre, Singapore
Phase 1 Completed
NCT00026195 2016-07-06
Irinotecan in Treating Aging Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00547547 2015-11-06
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00020488 2015-04-30
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01463982 2015-04-23
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT01141244 2014-04-10
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00046917 2014-02-24
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006095 2014-02-21
Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
Children's Oncology Group
Phase 1 Completed
NCT00054288 2014-01-13
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00112892 2014-01-13
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00004051 2013-12-19
Irinotecan in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005791 2013-12-19
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00021073 2013-12-11
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002939 2013-09-05
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
University of Chicago
Phase 1 Completed
NCT00004919 2013-07-02
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00016861 2013-06-26
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003742 2013-06-21
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00074321 2013-06-06
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00119236 2013-06-04
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003711 2013-05-30
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00084877 2013-05-16
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003109 2013-04-17
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
Fox Chase Cancer Center
Phase 1 Completed
NCT00024284 2013-04-05
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT00006000 2013-01-31
SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00079352 2013-01-25
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00062127 2013-01-24
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00808184 2012-11-01
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
National University Hospital, Singapore
Phase 4 Completed
NCT00003710 2012-08-09
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT00251407 2012-08-09
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00005068 2011-08-03
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT00020748 2011-03-24
Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer
Georgetown University
Phase 1 Completed
NCT00024141 2011-03-07
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00047242 2010-08-09
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00006465 2010-06-11
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00006485 2009-12-15
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004923 2009-08-25
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
Yale University
Phase 1/2 Completed